基于血清炎症因子水平变化及症状改善情况探究阿莫西林克拉维酸钾联合阿奇霉素在肺炎患儿中的应用价值
DOI:
CSTR:
作者:
作者单位:

六安市人民医院

作者简介:

通讯作者:

中图分类号:

基金项目:

安徽省卫生健康科研项目(AHWJ2023KYL0284)


Exploration of the application value of amoxicillin and clavulanate potassium combined with azithromycin in children with lobar pneumonia based on changes in serum inflammatory factor levels and symptom improvement
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
    摘要:

    目的:基于血清炎症因子水平变化及症状改善情况探究阿莫西林克拉维酸钾(AMC)联合阿奇霉素(AZM)在肺炎患儿中的应用价值。方法:回顾性选取2023年1月至2024年12月六安市人民医院收治的入院早期病原学结果尚未完全明确并接受经验性抗感染治疗的100例肺炎患儿的临床资料进行分析,依据临床用药方案分为对照组(50例,AMC治疗)和观察组(50例,AMC联合AZM治疗)。比较两组临床症状、炎症水平、肺功能、不良反应。结果:治疗3d后,观察组体温恢复正常、咳嗽消失比例、肺部啰音消失比例均显著高于对照组(观察组:90.00%、84.00%、88.00% VS 对照组:72.00%、62.00%、66.00%,P<0.05)。治疗后血清白介素(IL)-6、IL-8、肿瘤坏死因子-α(TNF-α)分别为6.41±1.56 pg/mL、12.64±2.41 pg/mL、14.36±2.47 pg/mL,均低于对照组(8.19±1.68 pg/mL、15.54±2.65 pg/mL、16.77±2.89 pg/mL,P<0.05)。肺功能方面,观察组第1 s用力呼气容积(FEV1)、用力肺活量(FVC)、最高呼气流量(PEF)分别为1.85±0.31 L、 2.08±0.38 L、 3.69±0.61 L/s,均高于对照组(1.62±0.29 L、1.73±0.36 L、3.05±0.58 L/s,P<0.05)。观察组不良反应发生率为10%,对照组为6%,两组差异无统计学意义(P>0.05)。结论:AMC联合AZM治疗能有效改善肺炎患儿的临床症状,降低炎症因子水平,改善肺功能,且安全性良好。

    Abstract:

    Objective:To explore the application value of amoxicillin and clavulanate potassium (AMC) combined with azithromycin (AZM) in children with pneumonia based on changes in serum inflammatory factor levels and symptom improvement. Methods:A retrospective analysis was conducted on the clinical data of 100 children with pneumonia who were admitted to Lu’an People’s Hospital from January 2023 to December 2024, whose etiological results were not definite in the early stage of admission, and who received empirical anti-infective therapy. According to clinical medication regimen, they were divided into the control group (50 cases, treated with AMC) and the observation group (50 cases, treated with AMC combined with AZM). Clinical symptoms, inflammatory levels, lung function, and adverse reactions were compared between the two groups. Results:After 3 d of treatment, the proportions of children with normal body temperature, children without cough, and children without lung rales in the observation group (90.00%, 84.00% and 88.00%) were significantly higher than those in the control group (72.00%, 62.00% and 66.00%) (P<0.05). After treatment, serum levels of interleukin (IL)-6, IL-8, and tumor necrosis factor-α (TNF-α) in the observation group [(6.41±1.56) pg/mL, (12.64±2.41) pg/mL and (14.36±2.47) pg/mL] were lower than those in the control group [(8.19±1.68) pg/mL, (15.54±2.65) pg/mL and (16.77±2.89) pg/mL] (P<0.05). For lung function, forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and peak expiratory flow (PEF) in the observation group [(1.85±0.31) L, (2.08±0.38) L and (3.69±0.61) L/s] were higher than those in the control group [(1.62±0.29) L, (1.73±0.36) L and (3.05±0.58) L/s] (P<0.05). The incidence of adverse reactions was 10% in the observation group and 6% in the control group, showing no statistically significant difference (P>0.05). Conclusion:AMC combined with AZM can effectively improve clinical symptoms, reduce inflammatory factor levels, and enhance lung function in children with pneumonia, with good safety.

    参考文献
    相似文献
    引证文献
引用本文
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2026-05-20
  • 最后修改日期:2026-06-08
  • 录用日期:2026-09-07
  • 在线发布日期:
  • 出版日期:
文章二维码